Table 1.
Clinicopathologic features among 58 advanced lung cancer patients
| Characteristics | Number | Percentage (%) |
|---|---|---|
| Gender | ||
| Male | 43 | 74.1 |
| Female | 15 | 25.9 |
| Age (years) | ||
| Mean | 62 years | |
| <60 | 27 | 46.6 |
| ≥60 | 31 | 53.4 |
| ECOG PS | ||
| 0–1 | 45 | 77.6 |
| 2 | 10 | 17.2 |
| 3 | 3 | 5.2 |
| Histologic type | ||
| Adenocarcinoma | 34 | 58.6 |
| Squamous | 16 | 27.6 |
| Small cell lung cancer | 6 | 10.3 |
| Other | 2 | 3.4 |
| Smoking status | ||
| No | 16 | 27.6 |
| Yes | 42 | 72.4 |
| EGFR mutation | ||
| Yes | 17 | 29.3 |
| No | 41 | 70.7 |
| Previous EGFR-TKI targeted treatment | ||
| Yes | 15 | 25.9 |
| No | 43 | 74.1 |
| Treatment lines of anlotinib | ||
| Third line | 31 | 53.4 |
| Further line | 27 | 46.6 |
| Receiving anlotinib dose | ||
| 12mg | 51 | 87.9 |
| 10mg | 7 | 12.1 |
| Previous anti-vascular drug therapy | ||
| Yes | 33 | 56.9% |
| No | 25 | 43.1% |
| Previous thoracic radiation therapy | ||
| Yes | 13 | 22.4% |
| No | 45 | 77.6% |
Abbreviations: ECOG PS: Eastern Cooperative Oncology Group performance status; EGFR: epidermal growth factor receptor; EGFR-TKI, epidermal growth factor receptor-tyrosine kinase inhibitor.